Browsing: Vaccine

mRNA-1644 utilizes Moderna’s messenger RNA (mRNA) technology to deliver a specific class of B cells needed to develop broadly neutralizing antibodies (bnAbs) to fight HIV infection. Inducing bnAbs is considered the primary goal of an HIV vaccine, and this requires B-cell activation.

The primary trial endpoints are safety and immunogenicity. The IAVI-sponsored clinical trial, IAVI G003, will test the safety and efficacy of vaccination with the HIV immunogen eOD-GT8 60mer, delivered via Moderna’s mRNA platform. eOD-GT8 60mer was developed by IAVI and Scripps Research teams and was initially tested in phase 1 clinical trial IAVI G001.

According to Contagion Live, IAVI G003 is expected to enroll 18 healthy, HIV-negative adults. The participants will receive 2 doses of eOD-GT8 60mer mRNA, which contains a portion of the viral sequence but cannot cause HIV infection. They will be monitored for safety for 6 months after their second dose, and their immune responses …

Three countries in Africa are being considered for regional vaccine production, the World Bank International Finance Corporation has declared. The three states include South Africa, Senegal, and Rwanda where investment towards setting up vaccine production is at an advanced stage.  

Why is this necessary now? 

When Covid-19 struck the continent and governments rushed to bring in vaccines to manage the global health crisis, the roll out of vaccines within the continent was marred by delays, scarcity and uncertainties.  

In Kenya for instance, when the first consignment came in, there was a wave of uncertainty that swept across the country especially because the government could not ascertain the availability of the second dose of the vaccine. However, 358,700 doses of the AstraZeneca-Oxford Covid-19 vaccine have just been received in Nairobi in a bid to help the government administer the vaccines to the population and manage the crisis. 

Meanwhile Zimbabwe has run

African leaders assembled at a global meeting to discuss the status of local pharmaceutical manufacturing on the continent, underscored the need to increase local production of vaccines and therapeutics to achieve greater public-health security.

“The production of vaccines and access to vaccines is an absolute priority,” Cyril Ramaphosa, President of South Africa, said Monday in opening remarks at the start of the two-day virtual meeting, convened by the African Union.

The meeting was attended by several African heads of state, health, finance, and trade ministers from across the continent, as well as officials from global financial institutions, foundations, pharmaceutical manufacturers, business leaders, and the general public. The African Development Bank was represented by Solomon Quaynor, Vice President Private Sector, Infrastructure, and Industrialization.

Although Africa consumes approximately one-quarter of global vaccines by volume, it manufactures less than 1% of its routine vaccines, with almost no outbreak vaccine manufacturing in place. The

Education is the lifeline of development in Africa.  At present, things are changing rapidly within the African education domain. Modern technology is now transforming learning in classrooms in South Africa, Nigeria, Kenya, Tanzania and Rwanda to mention a few. 
African states, just as other nations across the globe, are experiencing economic shocks from the coronavirus (COVID-19), which forced 250 million African children to stay home.  

Across the region, children were out of school for various periods. In Kenya, children remained home for the entire course of 2020 since March, while Tanzania’s school shutdown lasted for three months. …

Subscribe to unlock this article

Login to read this article for free and get 3 free premium articles. Subscribe today for unlimited premium articles and more.

Digital Subscription – Monthly

Monthly renewing
You can cancel anytime.

$5 /Monthly

Digital Subscription – Annually

Monthly renewing
You can cancel anytime.

$40